HRP20240765T1 - Pangenotipska sredstva protiv virusa influence i postupci njihove primjene - Google Patents
Pangenotipska sredstva protiv virusa influence i postupci njihove primjene Download PDFInfo
- Publication number
- HRP20240765T1 HRP20240765T1 HRP20240765TT HRP20240765T HRP20240765T1 HR P20240765 T1 HRP20240765 T1 HR P20240765T1 HR P20240765T T HRP20240765T T HR P20240765TT HR P20240765 T HRP20240765 T HR P20240765T HR P20240765 T1 HRP20240765 T1 HR P20240765T1
- Authority
- HR
- Croatia
- Prior art keywords
- oligonucleotide
- compound
- lna
- seq
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302548P | 2016-03-02 | 2016-03-02 | |
| EP20208373.9A EP3800257B1 (en) | 2016-03-02 | 2017-03-01 | Pan-genotypic agents against influenza virus and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240765T1 true HRP20240765T1 (hr) | 2024-09-13 |
Family
ID=59743201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240765TT HRP20240765T1 (hr) | 2016-03-02 | 2017-03-01 | Pangenotipska sredstva protiv virusa influence i postupci njihove primjene |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10597658B2 (https=) |
| EP (3) | EP3800257B1 (https=) |
| JP (3) | JP7536272B2 (https=) |
| CN (1) | CN108778344A (https=) |
| CA (1) | CA3014776A1 (https=) |
| DK (1) | DK3800257T3 (https=) |
| ES (1) | ES2981765T3 (https=) |
| FI (1) | FI3800257T3 (https=) |
| HR (1) | HRP20240765T1 (https=) |
| HU (1) | HUE066977T2 (https=) |
| LT (1) | LT3800257T (https=) |
| PL (1) | PL3800257T3 (https=) |
| PT (1) | PT3800257T (https=) |
| RS (1) | RS65707B1 (https=) |
| SI (1) | SI3800257T1 (https=) |
| SM (1) | SMT202400253T1 (https=) |
| WO (1) | WO2017151795A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021201996A1 (en) * | 2020-02-14 | 2021-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against respiratory viruses and methods of using the same |
| US12522827B2 (en) | 2016-03-02 | 2026-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
| US11339392B2 (en) | 2016-03-02 | 2022-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT69956A (en) * | 1990-08-14 | 1995-09-28 | Isis Pharmaceuticals Inc | Methode for inhibition of influenza virus by antiseuse oligonucleotides |
| US20040242518A1 (en) | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| AU2006235364A1 (en) * | 2005-04-08 | 2006-10-19 | Marina Biotech, Inc. | RNAi therapeutic for respiratory virus infection |
| EP1937066A4 (en) * | 2005-08-18 | 2008-12-24 | Alnylam Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES |
| WO2007084359A2 (en) * | 2006-01-17 | 2007-07-26 | Oligos Etc., Inc. | Compositions and methods for the treatment of influenza infection |
| CN100562342C (zh) * | 2006-01-17 | 2009-11-25 | 奥林格斯技术有限公司 | 防治流感病毒感染的寡核苷酸药物 |
| CA2666657A1 (en) * | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| US20090042823A1 (en) | 2007-08-10 | 2009-02-12 | Mdrna, Inc. | Uses of broad spectrum rnai therapeutics against influenza |
| CA2729757A1 (en) * | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| AU2009310557B2 (en) * | 2008-10-27 | 2014-09-11 | Academisch Ziekenhuis Leiden | Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA |
| EP2499248B1 (en) | 2009-11-13 | 2017-01-04 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| EP2519633B1 (en) * | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| CA2800281C (en) * | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
-
2017
- 2017-03-01 EP EP20208373.9A patent/EP3800257B1/en active Active
- 2017-03-01 RS RS20240693A patent/RS65707B1/sr unknown
- 2017-03-01 FI FIEP20208373.9T patent/FI3800257T3/fi active
- 2017-03-01 EP EP24159464.7A patent/EP4389221A3/en active Pending
- 2017-03-01 CN CN201780014078.0A patent/CN108778344A/zh active Pending
- 2017-03-01 CA CA3014776A patent/CA3014776A1/en active Pending
- 2017-03-01 US US16/081,818 patent/US10597658B2/en active Active
- 2017-03-01 SI SI201731528T patent/SI3800257T1/sl unknown
- 2017-03-01 SM SM20240253T patent/SMT202400253T1/it unknown
- 2017-03-01 HU HUE20208373A patent/HUE066977T2/hu unknown
- 2017-03-01 EP EP17760733.0A patent/EP3423107A4/en not_active Withdrawn
- 2017-03-01 ES ES20208373T patent/ES2981765T3/es active Active
- 2017-03-01 PT PT202083739T patent/PT3800257T/pt unknown
- 2017-03-01 LT LTEP20208373.9T patent/LT3800257T/lt unknown
- 2017-03-01 DK DK20208373.9T patent/DK3800257T3/da active
- 2017-03-01 JP JP2018543209A patent/JP7536272B2/ja active Active
- 2017-03-01 WO PCT/US2017/020241 patent/WO2017151795A1/en not_active Ceased
- 2017-03-01 PL PL20208373.9T patent/PL3800257T3/pl unknown
- 2017-03-01 HR HRP20240765TT patent/HRP20240765T1/hr unknown
-
2022
- 2022-10-07 JP JP2022162516A patent/JP2022176378A/ja not_active Withdrawn
-
2025
- 2025-04-02 JP JP2025061328A patent/JP2025096365A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3800257T3 (pl) | 2024-09-16 |
| DK3800257T3 (da) | 2024-06-24 |
| EP3423107A4 (en) | 2020-01-15 |
| JP2025096365A (ja) | 2025-06-26 |
| SMT202400253T1 (it) | 2024-09-16 |
| RS65707B1 (sr) | 2024-08-30 |
| US10597658B2 (en) | 2020-03-24 |
| JP2022176378A (ja) | 2022-11-25 |
| WO2017151795A1 (en) | 2017-09-08 |
| EP3800257A1 (en) | 2021-04-07 |
| EP4389221A3 (en) | 2024-11-20 |
| LT3800257T (lt) | 2024-07-25 |
| HUE066977T2 (hu) | 2024-09-28 |
| JP2019511471A (ja) | 2019-04-25 |
| EP4389221A2 (en) | 2024-06-26 |
| CA3014776A1 (en) | 2017-09-08 |
| JP7536272B2 (ja) | 2024-08-20 |
| US20190136242A1 (en) | 2019-05-09 |
| ES2981765T3 (es) | 2024-10-10 |
| EP3423107A1 (en) | 2019-01-09 |
| PT3800257T (pt) | 2024-06-26 |
| EP3800257B1 (en) | 2024-05-01 |
| FI3800257T3 (fi) | 2024-06-19 |
| SI3800257T1 (sl) | 2025-04-30 |
| CN108778344A (zh) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Genoyer et al. | The impact of defective viruses on infection and immunity | |
| Byrn et al. | Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit | |
| Workenhe et al. | Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes | |
| Goulet et al. | Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity | |
| HRP20210315T1 (hr) | Oligonukleotidi za smanjenje ekspresije pd-l1 | |
| Figlerowicz et al. | Genetic variability: The key problem in the prevention and therapy of RNA‐based virus infections | |
| Wong et al. | Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak | |
| Bray et al. | Experimental therapy of filovirus infections | |
| HRP20201125T1 (hr) | Antisens nukleinska kiselina | |
| SI2929031T1 (en) | PCSK9 IRNA assemblies and procedures for their use | |
| Suenaga et al. | An aptamer that binds efficiently to the hemagglutinins of highly pathogenic avian influenza viruses (H5N1 and H7N7) and inhibits hemagglutinin–glycan interactions | |
| PE20220574A1 (es) | Oligonucleotidos gapmer modificados y metodos de uso | |
| HRP20241138T1 (hr) | Oligonukleotidi za induciranje ekspresije očinskog ube3a | |
| HRP20192177T1 (hr) | Rnai pripravci za virus hepatitisa b (hbv) i postupci njihove upotrebe | |
| HRP20240765T1 (hr) | Pangenotipska sredstva protiv virusa influence i postupci njihove primjene | |
| HRP20160336T1 (hr) | Protusmjerna nukleinska kiselina | |
| WO2006121464A3 (en) | Compositions for treating respiratory viral infections and their use | |
| González Aparicio et al. | A virus is a community: diversity within negative-sense RNA virus populations | |
| Uematsu et al. | Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S-(4-nitrobenzyl)-6-thioinosine | |
| Perwitasari et al. | Targeting cell division cycle 25 homolog B to regulate influenza virus replication | |
| Stincarelli et al. | Reassortment ability of the 2009 pandemic H1N1 influenza virus with circulating human and avian influenza viruses: public health risk implications | |
| Golkar et al. | Inhibition of Ebola virus by anti-Ebola miRNAs in silico | |
| JP2019511471A5 (https=) | ||
| Ogidi et al. | Antiviral Therapeutics for Emerging Viruses | |
| Gaajetaan et al. | The type I interferon response during viral infections: a “SWOT” analysis |